期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (4)
Background In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term noninferior efficacy vs continuing tenofovir alafenamide-ba......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (3)
Background. Growing evidence indicates a causal relationship between SARS-CoV-2 infection and myocarditis. Post-authorization safety data have also id......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (3)
Background The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic zoonotic betacoronavirus and a global public health conc......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (3)
Background Long-acting injectable antiretroviral therapy (LAI-ART) is approved for treatment-naive or experienced people living with human immunodefic......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (4)
Background We explore severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow immunoassay (LFIA) performance under field co......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (3)
Background Although several coronavirus disease 2019 (COVID-19) vaccines initially showed high efficacy, there have been concerns because of waning im......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 77 (11)
Piperacillin-tazobactam (PTZ) is one of the most common antibiotics administered to hospitalized patients. Its broad activity against gram-negative, g......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (1)
Background. In people living with human immunodeficiency virus (HIV) (PLWH), individual polygenic risk scores (PRSs) are associated with coronary arte......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (7)
We report that people with human immunodeficiency virus (HIV) diagnosed with coronary artery atherosclerotic plaques display higher levels of HIV DNA ......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (8)
Background. This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus diseas......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (9)
In a population-representative sample, we observed a very high burden of long COVID and an estimated 7.3% of US adults (similar to 18 million adults) ......
期刊： CLINICAL INFECTIOUS DISEASES, 2023; 76 (10)
Background Data on antibody kinetics are limited among individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-......
